Healthcare -
Biotechnology - NASDAQ - US
$ 7.54
-5.16 %
$ 63.5 M
Market Cap
-0.54
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Karyopharm Therapeutics Inc.
| Net Income | -76.4 M |
| Depreciation & Amortization | -2.16 M |
| Capital Expenditures | -142 K |
| Stock-Based Compensation | 18.4 M |
| Change in Working Capital | 0 |
| Others | -67.3 M |
| Free Cash Flow | -128 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||
| Net Income | (76.4) | (143.1) | (165.3) | (124.1) | (196.3) | (199.6) | (178.4) | (129.0) | (109.6) | (118.2) | (75.8) | (33.9) | (15.9) | (10.3) |
| Depreciation & Amortization | (2.2) | 0.5 | 0.6 | 0.8 | 1.0 | 1.0 | 0.7 | 0.7 | 0.7 | 0.6 | 0.3 | 0.1 | 0.1 | 83 K |
| Deferred Income Tax | 0 | 0 | 0 | 1.5 | 0.9 | (1.4) | 29 K | 0 | 0 | 1.8 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 18.4 | 21.7 | 35.4 | 29.8 | 24.4 | 15.3 | 17.3 | 20.4 | 22.3 | 17.1 | 14.2 | 3.8 | 0.7 | 24 K |
| Other Operating Activities | (67.3) | (3.3) | (0.3) | 8.1 | 8.4 | 7.2 | 1.4 | 1.2 | 1.2 | 0.7 | 52 K | 88 K | 0.3 | 0 |
| Change in Working Capital | 0 | 31.4 | (20.0) | (23.2) | 1.4 | (13.3) | (0.2) | 33.0 | 1.0 | 4.0 | 9.7 | (0.4) | (0.4) | 1.7 |
| Cash From Operations | (127.5) | (92.7) | (149.6) | (107.1) | (160.2) | (190.8) | (159.1) | (73.7) | (84.4) | (94.0) | (51.4) | (30.3) | (15.5) | (8.5) |
| INVESTING CASH FLOW | ||||||||||||||
| Capital Expenditures | (0.1) | 0 | (0.1) | (5.7) | (0.1) | (0.2) | (2.4) | 62 K | 70 K | (1.4) | (2.8) | 57 K | (0.1) | (0.4) |
| Other Items | 95.6 | 7.9 | (104.1) | 147.6 | (53.5) | 78.7 | (105.3) | 17.2 | 24.7 | (89.4) | (64.2) | 0 | 0 | 0 |
| Cash From Investing Activities | 95.5 | 7.9 | (104.3) | 141.8 | (53.7) | 78.5 | (107.7) | 17.1 | 24.6 | (90.8) | (67.0) | 57 K | (0.1) | (0.4) |
| FINANCING CASH FLOW | ||||||||||||||
| Common Stock Repurchased | 111.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 83.3 | 0 | 0 | 0 | 0 | 0 | 166.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (41.7) | 1.1 | 4.0 | 63.7 | 10.3 | 78.1 | 3.5 | 0.9 | 0.6 | 0.6 | 0.3 | 72.8 | 9.5 | 12.0 |
| Cash From Financing Activities | 41.6 | 1.1 | 193.7 | 73.6 | 172.1 | 124.3 | 316.1 | 75.7 | 51.2 | 92.7 | 113.1 | 185.9 | 9.5 | 12.0 |
| CHANGE IN CASH | ||||||||||||||
| Net Change In Cash | 9.6 | (83.7) | (60.6) | 108.3 | (41.6) | 12.0 | 49.2 | 19.3 | (8.7) | (92.3) | (5.4) | 155.6 | (6.1) | 3.1 |
| FREE CASH FLOW | ||||||||||||||
| Free Cash Flow | (127.6) | (92.7) | (149.7) | (112.8) | (160.4) | (191.0) | (161.5) | (73.8) | (84.5) | (95.4) | (54.3) | (30.3) | (15.6) | (8.9) |